Compare VanEck Uranium & Nuclear ETF (NLR) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Uranium & Nuclear ETF vs Natera Inc. Common Stock — how do they compare? VanEck Uranium & Nuclear ETF trades at $94.43 (market cap $3.37B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 16.9× VanEck Uranium & Nuclear ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, VanEck Uranium & Nuclear ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Uranium & Nuclear ETF for 9 Days and Natera Inc. Common Stock for 0 Days on average.
| NLR | NTRA | |
|---|---|---|
Market Cap | $3.37B | $57.03B |
Volume | 376,734 | 1,131,157 |
Sector | Sector/Thematic | Health |
52-Week High | $164.37 | $425.64 |
52-Week Low | $94.52 | $179.42 |
Typical Hold Time | 9 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NLR, the VanEck Uranium and Nuclear ETF, trades at $99.38, down 0.82% on the day amid a bearish technical signal. The ETF is positioned to benefit from growing demand for nuclear power driven by AI data centers and government support, as highlighted by recent news of a major Google-Constellation deal and U.S. funding for new reactors. However, key financial ratios are unavailable, and technical indicators show selling pressure with moving averages and oscillators in bearish alignment.
The outlook for NLR is mixed, with long-term catalysts from nuclear energy adoption offset by near-term volatility and lack of transparent fundamentals. Risks include sector-specific headwinds and expense ratio comparisons, but institutional interest from firms like Bank of America suggests confidence. Investors should weigh the ETF's thematic exposure against its technical weakness and opaque financial metrics.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About VanEck Uranium & Nuclear ETF
VanEck Uranium and Nuclear ETF seeks exposure to companies involved in uranium mining and the nuclear power industry. Its holdings may include miners, utilities, reactor-related companies, and nuclear equipment or service providers.
Read more on NLR →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
